A simple algorithm to aid in the selection of appropriate disease modifying therapies (DMTs) reduces racial disparities in patients with relapsing multiple sclerosis (MS), early new research showed.
Plerixafor, a reversible CXCR4 antagonist, significantly increases the yield of CD34 + peripheral blood cells in randomized studies, thereby enabling more patients to proceed to autologous transplant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback